MCL1 and ovarian carcinoma: Previous human studies reported that high MCL-1 expression is associated with shorter survival times and poor outcomes in breast cancer, ovarian carcinoma, acute myeloid leukemia, and chronic lymphocytic leukemia [2, 10, 32, 33].